AccessibilityHelp
Silence Therapeutics Plc logo

Silence Therapeutics Plc(OTC) SLNCF

Market Cap$1.19BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)+383%
5 Year-13%
1 Year+298%
1 Month+59%
$6.37
+1.68%
+0.11Today
Silence Therapeutics Plc last closing stock price
MetricPriceDate
Last closeUSD 6.372026-10-22
Silence Therapeutics Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+65.45%USD 3.852026-10-09
1 month+59.25%USD 4.002026-08-27
3 month+324.67%USD 1.502026-07-02
Year to date+218.5%USD 2.002025-12-31
1 year+298.13%USD 1.602025-10-21
3 year+799.84%USD 0.712023-09-29
5 year-13.33%USD 7.352021-10-21
Since inception+382.58%USD 1.322007-12-27

Silence Therapeutics Plc Financials at a Glance

Market Cap

$1.19BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$614.29K

Net Income (TTM)

-$59.95M

EPS (TTM)

-$0.42

P/E Ratio

-15.06

Dividend

$0.00

Beta (Volatility)

-0.11 (Low)

Price

$6.37

Volume

2

Open

$6.38

Previous Close

$6.37

Daily Range

$6.37 - $6.38

52-Week Range

$1.06 - $6.38

Estimated Earnings Date

May 7, 2026

SLNCF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Silence Therapeutics Plc

Silence Therapeutics plc is a biotechnology firm based in London, focused on the discovery and development of innovative ribonucleic acid (RNA) therapeutics. The company specializes in addressing blood disorders, cardiovascular health, and other rare and metabolic diseases through its proprietary mRNAi GalNAc Oligonucleotide Discovery platform.

Products and Services
  • SLN360: In Phase I trials for cardiovascular disease treatment
  • SLN124: Targeting non-transfusion dependent thalassemia and myelodysplastic syndrome
  • Collaborations with AstraZeneca and Mallinckrodt for RNAi therapeutics
Growth Outlook
  • Strong pipeline with multiple candidates in clinical trials
  • Strategic partnerships enhance research and commercialization capabilities
  • Focus on expanding therapeutic applications in various disease areas
Financial Highlights
  • Recent quarterly revenue of $422,000, showing potential for growth
  • Cash and short-term investments of $72 million as of June 30, 2026
  • Operating expenses of $12.9 million in Q2 2026, reflecting ongoing R&D investments
Silence Therapeutics is positioned in a promising sector, leveraging its advanced RNA technology to develop targeted therapies. The company’s strategic partnerships with industry leaders like AstraZeneca and Mallinckrodt Pharma enhance its research capabilities and market reach. With a robust pipeline and significant cash reserves, Silence Therapeutics is well-equipped to navigate the complexities of the biotechnology landscape. The recent quarterly performance indicates a commitment to innovation and growth, making it an intriguing option for investors interested in the biotechnology sector.
AI Generated • Oct 9, 2026

Industry

Biotechnology

Sector

Health Care

Employees

88

CEO

Iain Gladstone Ross

Website

www.silence-therapeutics.com

Headquarters

London, GL W6 7AP, GB

SLNCF Financials

Key Financial Metrics (TTM)

Gross Margin

51.00%

Operating Margin

-10880.25%

Net Income Margin

-9759.23%

Return on Equity

-106.94%

Return on Capital

-143.69%

Return on Assets

-56.34%

Earnings Yield

-6.64%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.19BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

186.46M

Volume

2

Avg. Volume

234.523

Financials (TTM)

Gross Profit

$313.29K

Operating Income

-$66.84M

EBITDA

-$60.29M

Operating Cash Flow

-$42.29M

Capital Expenditure

-$58.00K

Free Cash Flow

-$42.34M

Cash & ST Invst.

$72.05M

Total Debt

$112.00K

Silence Therapeutics Plc Performance Analysis

Silence Therapeutics Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 21,557,38526.3%
20232023-12-31USD 31,643,00046.8%
20242024-12-31USD 43,258,00036.7%
20252025-12-31USD 559,000-98.7%
Silence Therapeutics Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-48.2%
Q42025-12-31-78.6%
Q12026-03-311139.1%
Q22026-06-30-100.0%
Silence Therapeutics Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.52-15.2%
20232023-12-31USD -0.49-5.6%
20242024-12-31USD -0.33-33.0%
20252025-12-31USD -0.6391.5%
Silence Therapeutics Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3045.0%
Q42025-12-3143.2%
Q12026-03-31-28.0%
Q22026-06-3018.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

-$108.20K

-156.8%

Gross Margin

0.00%

N/A

Market Cap

$1.19BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$13.50M

N/A

Employees

88

N/A

Net Income

-$12.29M

+67.2%

EBITDA

-$13.00M

+57.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$72.05M

-36.9%

Total Debt

$112.00K

N/A

Accounts Receivable

$9.29M

-53.6%

Inventory

$0.00

N/A

Long Term Debt

$9.00K

N/A

Short Term Debt

$103.00K

N/A

Return on Assets

-56.34%

N/A

Return on Invested Capital

-71.33%

N/A

Free Cash Flow

$1.49M

+106.8%

Operating Cash Flow

$1.49M

+106.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
WVEWave Life Sciences Ltd.
$3.18-5.07%
SRPTSarepta Therapeutics, Inc.
$17.73-2.48%
ADRXADARx Pharmaceuticals, Inc.
$17.63-0.28%
BNTCBenitec Biopharma Inc.
$8.65-1.93%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$147.49+1.89%
TAT&T
$20.93-7.96%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$83.56+1.77%
NUNu Holdings
$15.16+2.92%

Questions About SLNCF

What is the current price of Silence Therapeutics Plc?

Silence Therapeutics Plc is trading at $6.37 per share.

What is the 52-week range for Silence Therapeutics Plc?

Over the past 52 weeks, Silence Therapeutics Plc has traded between $1.06 and $6.38.

How much debt does Silence Therapeutics Plc have?

As of the most recent reporting period, Silence Therapeutics Plc reported total debt of $112.00K.

How much cash does Silence Therapeutics Plc have on hand?

Silence Therapeutics Plc reported $72.05M in cash and cash equivalents in its most recent financial results.

What is Silence Therapeutics Plc’s dividend yield?

Silence Therapeutics Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services